GREENWICH LIFESCIENCES INC(NASDAQ:GLSI) stock Fundamental Analysis

Fundamental Rating

Overall GLSI gets a fundamental rating of 2 out of 10. We evaluated GLSI against 571 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for GLSI as it has an excellent financial health rating, but there are worries on the profitability. GLSI is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

GLSI had negative earnings in the past year.

GLSI had a negative operating cash flow in the past year.

In the past 5 years GLSI always reported negative net income.

GLSI had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

GLSI has a Return On Assets of -180.18%. This is amonst the worse of the industry: GLSI underperforms 88.45% of its industry peers.

The Return On Equity of GLSI (-210.64%) is worse than 69.80% of its industry peers.

		Industry Rank	Sector Rank
ROA	-180.18%
ROE	-210.64%
ROIC	N/A

ROA(3y)-67.33%

ROA(5y)-2328.36%

ROE(3y)-69.67%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GLSI so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

GLSI has about the same amout of shares outstanding than it did 1 year ago.

The number of shares outstanding for GLSI has been increased compared to 5 years ago.

GLSI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 92.80 indicates that GLSI is not in any danger for bankruptcy at the moment.

The Altman-Z score of GLSI (92.80) is better than 99.29% of its industry peers.

There is no outstanding debt for GLSI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	92.8

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 6.91 indicates that GLSI has no problem at all paying its short term obligations.

GLSI has a better Current ratio (6.91) than 66.61% of its industry peers.

A Quick Ratio of 6.91 indicates that GLSI has no problem at all paying its short term obligations.

GLSI has a better Quick ratio (6.91) than 66.79% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	6.91
Quick Ratio	6.91

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for GLSI have decreased strongly by -14.24% in the last year.

EPS 1Y (TTM)-14.24%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-6.87%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

GLSI is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -9.14% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-17.65%

EPS Next 2Y-9.14%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GLSI. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GLSI. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as GLSI's earnings are expected to decrease with -9.14% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-9.14%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for GLSI!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GREENWICH LIFESCIENCES INC

NASDAQ:GLSI (2/21/2025, 8:23:57 PM)

After market: 11.95 0 (0%)

11.95

-0.09 (-0.75%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-14 2024-11-14/amc

Earnings (Next)04-14 2025-04-14/amc

Inst Owners8.43%

Inst Owner Change-99.67%

Ins Owners55.06%

Ins Owner Change0.2%

Market Cap157.02M

Analysts82.86

Price Target38.76 (224.35%)

Short Float %10.9%

Short Ratio18.78

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)4.3%

Min EPS beat(2)1.96%

Max EPS beat(2)6.63%

EPS beat(4)3

Avg EPS beat(4)3.13%

Min EPS beat(4)-2.94%

Max EPS beat(4)6.86%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-23.53%

EPS NY rev (1m)1.23%

EPS NY rev (3m)1.23%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	31.51
P/tB	31.53
EV/EBITDA	N/A

EPS(TTM)-0.8

EYN/A

EPS(NY)-0.83

Fwd EYN/A

FCF(TTM)-0.58

FCFYN/A

OCF(TTM)-0.58

OCFYN/A

SpS0

BVpS0.38

TBVpS0.38

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-180.18%
ROE	-210.64%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-67.33%

ROA(5y)-2328.36%

ROE(3y)-69.67%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	6.91
Quick Ratio	6.91
Altman-Z	92.8

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-14.24%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-6.87%

EPS Next Y-17.65%

EPS Next 2Y-9.14%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-14.75%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-20.4%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-20.4%

OCF growth 3YN/A

OCF growth 5YN/A

GREENWICH LIFESCIENCES INC (GLSI) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens